@article{JGO27151,
author = {Julie M. Jiang and Nitin Ohri and Justin Tang and Renee Moadel and Jacob Cynamon and Andreas Kaubisch and Milan Kinkhabwala and Madhur K. Garg and Chandan Guha and Rafi Kabarriti},
title = {Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {10},
number = {3},
year = {2019},
keywords = {},
abstract = {Background: Higher facility volume is correlated to better overall survival (OS), but there is little knowledge on the effect of facility treatment modality number on OS in hepatocellular carcinoma (HCC).
Methods: This is a retrospective analysis of data from the National Cancer Database (NCDB) from 2004–2014 on patients with non-metastatic HCC. Treatment modalities assessed were surgical resection, transplantation, ablation, radioembolization, stereotactic body radiation therapy (SBRT), single-agent chemotherapy, and multi-agent chemotherapy. Facilities were dichotomized at the median of the listed treatment modalities.
Results: There were a total of 112,512 patients with non-metastatic HCC. Of a total of 1,230 sites, 830 (67.5%) used four or fewer modalities. Average survival for patients treated at facilities using fewer modalities was 12.0 and 23.5 months for those treated at facilities with more modalities [hazard ratio (HR) =0.52, 95% confidence interval (CI): 0.51–0.53, P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/27151}
}